Impact of the COVID-19 Pandemic and Lockdown on Cancer Diagnoses Using Swiss Cantonal Cancer Registry Data.

Impact of the COVID-19 Pandemic and Lockdown on Cancer Diagnoses Using Swiss Cantonal Cancer Registry Data.

Publication date: Oct 03, 2024

Background/Objectives: This study aims to investigate differences in cancer diagnosis based on absolute case numbers and age-standardized incidence rate ratios (IRRs) in the pre-Coronavirus disease 2019 (COVID-19) years (2018/19) and the first two years of the COVID-19 pandemic (2020, 2021) in two Swiss cantons. Methods: Data of the Swiss cantonal cancer registry of the cantons of Zurich (ZH) and Zug (ZG) were used to descriptively investigate differences in annual and monthly absolute numbers regarding all-cancer and the five most common cancer types. Directly age-standardized monthly incidence rates (IRs) were calculated. Multivariate Quasipoisson regression models were fitted to determine the IRRs with 95% confidence intervals (95% CI). Results: Annual absolute numbers of all investigated cancers were similar in 2018/19, 2020, and 2021, except for prostate cancer (increase of 20. 8% in 2021 compared to 2018/19). In 2020, there were generally more cancer diagnoses in January and February followed by a decrease in April and May. Compared to the pre-COVID-19 period, lower IRs were observed in 2020 for all-cancer (IRR = 0. 96 [95% CI 0. 96, 0. 97]) and female breast cancer (0. 92 [0. 89, 0. 96]), whereas higher IRs were observed in 2021 for all-cancer (1. 02 [1. 02, 1. 02]) and prostate cancer (1. 23 [1. 18, 1. 28]). Conclusions: Cancer detection and diagnoses decreased during the first year of the pandemic, especially during the most stringent lockdown phase in April. The findings of this study may inform the decisions of policymakers and public health system during future pandemics.

Open Access PDF

Concepts Keywords
Cancer cancer registry
Irs coronavirus disease 2019
Policymakers regression analysis
Zurich Switzerland

Semantics

Type Source Name
disease MESH COVID-19 Pandemic
disease MESH Cancer
disease MESH prostate cancer
pathway KEGG Prostate cancer
disease MESH breast cancer
pathway KEGG Breast cancer
drug DRUGBANK Coenzyme M
disease MESH morbidity
disease MESH infections
disease MESH melanoma
pathway KEGG Melanoma
disease MESH colorectal cancer
pathway KEGG Colorectal cancer
drug DRUGBANK Aspartame
disease MESH lung cancer
disease IDO process
disease MESH missed diagnoses
disease IDO country
disease IDO quality
drug DRUGBANK Elm
drug DRUGBANK Diethylstilbestrol

Original Article

(Visited 2 times, 1 visits today)